Neurocrine Biosciences Inc (NBIX) stock
NBIXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 19/306% below fair value
$162.86−3.06 (-1.84%)
Close on Nov 18, 2026Market cap $16.55BP/E 23.9Yield –
Neurocrine Biosciences operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Neurocrine Biosciences's operating income for the twelve months ending Jun 30, 2026 was $794.80M, up 60.6% year over year. For fiscal 2025 it was $619.10M, up 8.5% from the year before. The highest annual figure on record is $619.10M in fiscal 2025.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $619.10M | +8.5% |
| FY2024 | Dec 31, 2024 | $570.50M | +127.4% |
| FY2023 | Dec 31, 2023 | $250.90M | +0.8% |
| FY2022 | Dec 31, 2022 | $249.00M | +142.9% |
| FY2021 | Dec 31, 2021 | $102.50M | -37.1% |
| FY2020 | Dec 31, 2020 | $163.00M | +125.4% |
| FY2019 | Dec 31, 2019 | $72.30M | +96.5% |
| FY2018 | Dec 31, 2018 | $36.80M | – |
| FY2017 | Dec 31, 2017 | -$131.36M | – |
| FY2016 | Dec 31, 2016 | -$147.37M | – |
| FY2015 | Dec 31, 2015 | -$94.20M | – |
| FY2014 | Dec 31, 2014 | -$64.41M | – |
| FY2013 | Dec 31, 2013 | -$49.68M | -3530.8% |
| FY2012 | Dec 31, 2012 | $1.45M | -95.7% |
| FY2011 | Dec 31, 2011 | $33.92M | – |
| FY2010 | Dec 31, 2010 | -$13.72M | – |
| FY2009 | Dec 31, 2009 | -$53.67M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $151.50M | +4.1% |
| Q1 FY2026 | Mar 31, 2026 | $193.40M | +719.5% |
| Q4 FY2025 | Dec 31, 2025 | $210.90M | +48.5% |
| Q3 FY2025 | Sep 30, 2025 | $239.00M | +30.0% |
| Q2 FY2025 | Jun 30, 2025 | $145.60M | +0.1% |
| Q1 FY2025 | Mar 31, 2025 | $23.60M | -76.2% |
| Q4 FY2024 | Dec 31, 2024 | $142.00M | -5.5% |
| Q3 FY2024 | Sep 30, 2024 | $183.80M | +30.2% |
| Q2 FY2024 | Jun 30, 2024 | $145.40M | +97.6% |
| Q1 FY2024 | Mar 31, 2024 | $99.30M | – |
| Q4 FY2023 | Dec 31, 2023 | $150.30M | +45.4% |
| Q3 FY2023 | Sep 30, 2023 | $141.20M | +60.8% |
| Q2 FY2023 | Jun 30, 2023 | $73.60M | +34.6% |
| Q1 FY2023 | Mar 31, 2023 | -$114.20M | -3783.9% |
| Q4 FY2022 | Dec 31, 2022 | $103.40M | – |
| Q3 FY2022 | Sep 30, 2022 | $87.80M | +97.3% |
| Q2 FY2022 | Jun 30, 2022 | $54.70M | -12.9% |
| Q1 FY2022 | Mar 31, 2022 | $3.10M | -90.2% |
| Q4 FY2021 | Dec 31, 2021 | -$36.30M | -150.6% |
| Q3 FY2021 | Sep 30, 2021 | $44.50M | – |
| Q2 FY2021 | Jun 30, 2021 | $62.80M | -18.0% |
| Q1 FY2021 | Mar 31, 2021 | $31.50M | -46.5% |
| Q4 FY2020 | Dec 31, 2020 | $71.80M | +47.1% |
| Q3 FY2020 | Sep 30, 2020 | -$44.30M | -149.2% |
| Q2 FY2020 | Jun 30, 2020 | $76.60M | +122.7% |
| Q1 FY2020 | Mar 31, 2020 | $58.90M | – |
| Q4 FY2019 | Dec 31, 2019 | $48.80M | +124.1% |
| Q3 FY2019 | Sep 30, 2019 | $90.10M | +65.9% |
| Q2 FY2019 | Jun 30, 2019 | $34.40M | – |
| Q1 FY2019 | Mar 31, 2019 | -$101.00M | – |
| Q4 FY2018 | Dec 31, 2018 | $21.78M | +84.0% |
| Q3 FY2018 | Sep 30, 2018 | $54.32M | – |
| Q2 FY2018 | Jun 30, 2018 | -$1.85M | – |
| Q1 FY2018 | Mar 31, 2018 | -$37.45M | – |
| Q4 FY2017 | Dec 31, 2017 | $11.83M | – |
| Q3 FY2017 | Sep 30, 2017 | -$6.00M | – |
| Q2 FY2017 | Jun 30, 2017 | -$57.27M | – |
| Q1 FY2017 | Mar 31, 2017 | -$79.93M | – |
| Q4 FY2016 | Dec 31, 2016 | -$46.25M | – |
| Q3 FY2016 | Sep 30, 2016 | -$38.44M | – |
See a number that looks wrong?